Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol. Key products include Korlym (and its authorized generic) for hypercortisolism and Lifyorli (relacorilant), which received FDA approval in March 2026 for platinum-resistant ovarian cancer and began commercial distribution in April 2026.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
3 Months Ended June 30, 2025 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net Product Revenue | $256,147 | $194,430 | $421,050 | $351,644 |
| Cost of Sales | $4,061 | $3,433 | $6,944 | $5,836 |
| Gross Margin % | 98.4% | 98.2% | 98.4% | 98.3% |
| Operating Expenses | $214,847 | $167,755 | $429,351 | $321,553 |
| Operating Income (Loss) | $41,300 | $26,675 | $(8,301) | $30,091 |
| Net Income | $42,987 | $35,149 | $11,226 | $55,696 |
| Diluted EPS | $0.36 | $0.29 | $0.09 | $0.46 |
| Cash & Cash Equivalents (Balance Sheet) |
$111,039 (as of June 30, 2026) | |||
| Total Marketable Securities (Balance Sheet) |
$433,609 (as of June 30, 2026) | |||
| Net Cash from Operating Activities | N/A | $16,771 | $49,067 |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 31.7% year-over-year for the quarter and 19.7% for the six-month period. This was driven by higher sales of Hypercortisolism Products and the commercial launch of Lifyorli in April 2026, which generated $47.6 million in revenue for the quarter.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose significantly to $156.9 million for the quarter (up from $103.9 million in 2025) due to increased sales and marketing activities for Lifyorli and Hypercortisolism Products. Research and development (R&D) expenses decreased slightly to $53.9 million as certain development programs neared completion.
- Profitability: While the company reported a net income of $43.0 million for the quarter, the six-month period resulted in a net income of only $11.2 million compared to $55.7 million in the prior year. This decline was primarily due to higher operating expenses and a decrease in stock-based compensation tax benefits.
- Cash Flow: Net cash provided by operating activities decreased to $16.8 million for the six months ended June 30, 2026, from $49.1 million in the prior year, reflecting lower net income and changes in working capital.
Guidance, Outlook, and Risks
- Regulatory Outlook: The FDA issued a Complete Response Letter (CRL) in December 2025 regarding the NDA for relacorilant for hypercortisolism. Corcept resubmitted the NDA on June 17, 2026, with a Prescription Drug User Fee Act target decision date of December 17, 2026. An MAA for Lifyorli in the EU is expected to receive a decision in Q4 2026.
- Legal Proceedings:
- Securities Class Action: A lawsuit filed in February 2026 alleges false statements regarding the relacorilant NDA. The company intends to vigorously defend itself.
- Patent Litigation: The Federal Circuit affirmed a lower court ruling in February 2026 finding no infringement of Corcept's patents by Teva's generic Korlym. Corcept's petition for rehearing was denied in July 2026.
- Antitrust Litigation: Teva and other plaintiffs have filed antitrust lawsuits alleging unfair business practices. The Teva case is scheduled for trial in March 2027.
- Risk Factors: Key risks include the potential impact of the Inflation Reduction Act (IRA) on Medicare reimbursement, the availability of generic versions of Korlym, and the outcome of ongoing litigation. The company also faces risks related to the political and regulatory environment regarding mifepristone (the active ingredient in Korlym).
- Liquidity: As of June 30, 2026, the company held $544.6 million in cash, cash equivalents, and marketable securities. Management expects to fund operations for the next 12 months without raising additional capital.
Investor Verification Checklist
- Lifyorli Commercialization: Verify the adoption rate and reimbursement status of Lifyorli following its April 2026 launch.
- Relacorilant NDA Status: Monitor the FDA's review progress for the resubmitted NDA for hypercortisolism, with a decision expected by December 17, 2026.
- Generic Competition: Assess the market impact of Teva's generic Korlym and potential future generic entrants (Sun, Hikma) following the patent litigation outcomes.
- Legal Exposure: Track developments in the securities class action and antitrust lawsuits, particularly the March 2027 trial date for the Teva antitrust case.
- Regulatory Policy: Evaluate the potential financial impact of the Inflation Reduction Act (IRA) and the "One Big Beautiful Bill Act" (OBBBA) on future revenue and reimbursement rates.